|
1.
|
A InoueY SaijoM MaemondoSevere acute
interstitial pneumonia and
gefitinibLancet361137139200310.1016/S0140-6736(03)12190-312531582
|
|
2.
|
D MakrisA ScherpereelM CopinFatal
interstitial lung disease associated with oral erlotinib therapy
for lung cancerBMC
Cancer7150200710.1186/1471-2407-7-15017683587
|
|
3.
|
V LiuD WhiteM ZakowskiPulmonary toxicity
associated with
erlotinibChest13210421044200710.1378/chest.07-005017873198
|
|
4.
|
M AndoI OkamotoN YamamotoPredictive
factors for interstitial lung disease, antitumor response, and
survival in non-small-cell lung cancer patients treated with
gefitinibJ Clin
Oncol2425492556200610.1200/JCO.2005.04.986616735708
|
|
5.
|
CL ChouHW KoCW WangCT YuHP KuoCD
HuangErlotinib-associated near-fatal interstitial pneumonitis in a
patient with relapsed lung adenocarcinomaChang Gung Med
J33100105201020184801
|
|
6.
|
B VahidA EsmailiErlotinib-associated acute
pneumonitis: report of two casesCan Respir J Can Thorac
Soc14167170200717464382
|
|
7.
|
Y Del CastilloP EspinosaF BodíInterstitial
lung disease associated to erlotinib treatment: a case reportCases
J359201020509858
|
|
8.
|
I DimopoulouA BamiasP LyberopoulosMA
DimopoulosPulmonary toxicity from novel antineoplastic agentsAnn
Oncol17372379200610.1093/annonc/mdj05716291774
|
|
9.
|
MM PeerzadaTP SpiroHA DawPulmonary
toxicities of tyrosine kinase inhibitorsClin Adv Hematol
Oncol9824836201122252615
|
|
10.
|
JH MinHY LeeH LimDrug-induced interstitial
lung disease in tyrosine kinase inhibitor therapy for non-small
cell lung cancer: a review on current insightCancer Chemother
Pharmacol6810991109201110.1007/s00280-011-1737-221913033
|
|
11.
|
TS MokYL WuS ThongprasertGefitinib or
carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J
Med361947957200910.1056/NEJMoa081069919692680
|
|
12.
|
M MaemondoA InoueK KobayashiGefitinib or
chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl
J Med36223802388201010.1056/NEJMoa090953020573926
|
|
13.
|
TJ LynchDW BellR SordellaActivating
mutations in the epidermal growth factor receptor underlying
responsiveness of non-small-cell lung cancer to gefitinibN Engl J
Med35021292139200410.1056/NEJMoa04093815118073
|
|
14.
|
JG PaezPA JanneJC LeeEGFR mutations in
lung cancer: correlation with clinical response to gefitinib
therapyScience3041497500200410.1126/science.109931415118125
|
|
15.
|
R SordellaDW BellDA HaberJ
SettlemanGefitinib-sensitizing EGFR mutations in lung cancer
activate anti-apoptotic
pathwaysScience30511631167200410.1126/science.110163715284455
|
|
16.
|
MH CohenJR JohnsonR PazdurU.S. food and
drug administration drug approval summary: conversion of imatinib
mesylate (sti571; gleevec) tablets from accelerated approval to
full approvalClin Cancer Res111219200515671523
|
|
17.
|
K TakeuchiF ItoReceptor tyrosine kinases
and targeted cancer therapeuticsBiol Pharm
Bull3417741780201110.1248/bpb.34.177422130229
|
|
18.
|
L RicheldiU CostabelM SelmanEfficacy of a
tyrosine kinase inhibitor in idiopathic pulmonary fibrosisN Engl J
Med36510791087201110.1056/NEJMoa110369021992121
|
|
19.
|
BA KeoghRG CrystalAlveolitis: the key to
the interstitial lung
disordersThorax37110198210.1136/thx.37.1.17041320
|
|
20.
|
TE King JrA PardoM SelmanIdiopathic
pulmonary
fibrosisLancet37819491961201110.1016/S0140-6736(11)60052-4
|
|
21.
|
WS ChenCS LazarM PoenieRequirement for
intrinsic protein tyrosine kinase in the immediate and late actions
of the EGF receptorNature328820823198710.1038/328820a03498122
|
|
22.
|
Y YardenMX SliwkowskiUntangling the ErbB
signalling networkNat Rev Mol Cell
Biol2127137200110.1038/3505207311252954
|
|
23.
|
H SuzukiK AoshibaN YokohoriA
NagaiEpidermal growth factor receptor tyrosine kinase inhibition
augments a murine model of pulmonary fibrosisCancer
Res6350545059200312941834
|
|
24.
|
DK MadtesHK BusbyTP StrandjordJG
ClarkExpression of transforming growth factor-alpha and epidermal
growth factor receptor is increased following bleomycin-induced
lung injury in ratsAm J Respir Cell Mol
Biol11540551199410.1165/ajrcmb.11.5.75245667524566
|
|
25.
|
M SelmanTE KingA PardoAmerican Thoracic
Society; European Respiratory Scoiety; American College of Chest
PhysiciansIdiopathic pulmonary fibrosis: prevailing and evolving
hypotheses about its pathogenesis and implications for therapyAnn
Intern
Med134136151200110.7326/0003-4819-134-2-200101160-0001511177318
|
|
26.
|
RP BaughmanEE LowerMA MillerPA BejaranoSC
HeffelfingerOverexpression of transforming growth factor-alpha and
epidermal growth factor-receptor in idiopathic pulmonary
fibrosisSarcoidosis Vasc Diffuse Lung Dis165761199910207942
|
|
27.
|
WD HardieDR ProwsA
Piljan-GentleDose-related protection from nickel-induced lung
injury in transgenic mice expressing human transforming growth
factor-alphaAm J Respir Cell Mol
Biol26430437200210.1165/ajrcmb.26.4.459411919079
|
|
28.
|
BR SmithWR BrianThe role of metabolism in
chemical-induced pulmonary toxicityToxicol
Pathol19470481199110.1177/0192623391019004151813990
|
|
29.
|
FP GuengerichPurification and
characterization of xenobiotic-metabolizing enzymes from lung
tissuePharmacol
Ther45299308199010.1016/0163-7258(90)90068-D2405438
|
|
30.
|
TR DevereuxBA DominRM PhilpotXenobiotic
metabolism by isolated pulmonary cellsPharmacol
Ther41243256198910.1016/0163-7258(89)90109-52652151
|
|
31.
|
RA RothJF ReindelLung vascular injury from
monocrotaline pyrrole, a putative hepatic metaboliteAdv Exp Med
Biol283477487199110.1007/978-1-4684-5877-0_641906225
|
|
32.
|
DE WilliamsRL ReedG KedzierskiGA DannanFP
GuengerichDR BuhlerBioactivation and detoxication of the
pyrrolizidine alkaloid senecionine by cytochrome P-450 enzymes in
rat liverDrug Metab Dispos1738739219892571477
|
|
33.
|
D McKillopAD McCormickA MillarGS MilesPJ
PhillipsM HutchisonCytochrome P450-dependent metabolism of
gefitinibXenobiotica353950200510.1080/0049825040002646415788367
|
|
34.
|
J LiM ZhaoP HeM HidalgoSD
BakerDifferential metabolism of gefitinib and erlotinib by human
cytochrome P450 enzymesClin Cancer
Res37313737200710.1158/1078-0432.CCR-07-008817575239
|
